Kenneth N. Drew, Vice President, Flamma USA, FLAMMA


e-version image

Click HERE to download the PDF



Flamma has a long history of dealing with high value chiral materials such as amino acid derivatives. How is this seen from innovator companies developing traditional small molecule APIs and/or peptide drugs?

If your small molecule has a chiral piece within its structure, you should be speaking with Flamma. In fact, other competitors within the CDMO space often contact us to see if Flamma can make the necessary intermediate or RSM for them.

With this said, Flamma has a portfolio of projects in which many of the molecules being developed contain no chirality at all. This is a testament about the service that Flamma has provided over the years and the word-of-mouth reviews and recommendations from within the industry. Flamma never promises that we can do it al ... ...